Pharmacological Therapy in COMPANION Study: Compliance and Dosage
A widely used definition of heart failure is ‘failure of the heart to maintain systemic perfusion commensurate with the requirements of metabolizing tissues.’ This definition and view of myocardial failure dominated the development of medical treatment strategies for the clinical syndrome of heart failure between the mid-1960s and the mid-1980s (the cardiorenal model), and the pharmacological approaches in this period were designed to bring about an acute increase in the performance of weakened heart muscle. Myocardial systolic dysfunction is best demonstrated as a downward and rightward shift in the Frank-Starling relation or a plot of preload or resting length versus myocardial performance. It was largely because positive inotropic agents can acutely shift the cardiac output/preload relation upward and to the left that the initial attempts to improve the natural history of chronic heart failure (CHF) took the form of these types of pharmacological therapy.
KeywordsHeart Failure Chronic Heart Failure Isosorbide Dinitrate Angiotensin Receptor Antagonist Overt Heart Failure
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Mann DL (1999) Mechanisms and models in heart failure. Circulation 100:999–1008PubMedCrossRefGoogle Scholar
Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248–254PubMedCrossRefGoogle Scholar
Eichhorn EJ, Bristow MR (1996) Medical therapy can improve the biologic properties of chronically failing heart: a new era in the treatment of heart failure. Circulation 94:2285–2296PubMedCrossRefGoogle Scholar
The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533CrossRefGoogle Scholar
The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 316:1429–1435CrossRefGoogle Scholar
The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302CrossRefGoogle Scholar
Pitt B, Zannad F, Remme WJ et al for the Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709–717PubMedCrossRefGoogle Scholar
Packer M, Bristow MR, Cohn JN et al for the US Carvedilol Heart Failure Study Group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355PubMedCrossRefGoogle Scholar
Packer M, Coats AJS, Fowler MB et al (2001) Effect of carvedilol in severe chronic heart failure. N Engl J Med 344:1651–1658PubMedCrossRefGoogle Scholar
Remme WJ (1997) The treatment of heart failure. (The Task Force of the Working Group on Heart Failure of the European Society of Cardiology) Eur Heart J 18:736–753CrossRefGoogle Scholar
© Springer-Verlag Italia 2004